Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNG456 Monotherapy and in Combination With Abemaciclib in Solid Tumors With MTAP Loss
NCT06810544Phase 2Recruiting
- Sponsor
- Tango Therapeutics
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TNG456 in solid tumor, non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) (7 arms), sponsored by Tango Therapeutics. Primary endpoints: Maximum Tolerated Dose at 21 days, Phase 2 Anti-neoplastic Activity Single Agent at 18 weeks and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
TNG456
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT06810544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810544.